260 related articles for article (PubMed ID: 35203733)
41. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Arca-Suárez J; Fraile-Ribot P; Vázquez-Ucha JC; Cabot G; Martínez-Guitián M; Lence E; González-Bello C; Beceiro A; Rodríguez-Iglesias M; Galán-Sánchez F; Bou G; Oliver A
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383659
[TBL] [Abstract][Full Text] [Related]
42. Genomic Characterization of Mutli-Drug Resistant
Bitar I; Salloum T; Merhi G; Hrabak J; Araj GF; Tokajian S
Front Cell Infect Microbiol; 2022; 12():922976. PubMed ID: 35782142
[TBL] [Abstract][Full Text] [Related]
43. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
Castanheira M; Doyle TB; Mendes RE; Sader HS
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
[TBL] [Abstract][Full Text] [Related]
44. Extensively Drug-Resistant
Khan A; Tran TT; Rios R; Hanson B; Shropshire WC; Sun Z; Diaz L; Dinh AQ; Wanger A; Ostrosky-Zeichner L; Palzkill T; Arias CA; Miller WR
Open Forum Infect Dis; 2019 Jul; 6(7):ofz273. PubMed ID: 31281867
[TBL] [Abstract][Full Text] [Related]
45. Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa.
Teo JQ; Lim JC; Tang CY; Lee SJ; Tan SH; Sim JH; Ong RT; Kwa AL
mSphere; 2021 Jan; 6(1):. PubMed ID: 33504661
[TBL] [Abstract][Full Text] [Related]
46. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Sader HS; Carvalhaes CG; Streit JM; Doyle TB; Castanheira M
Microb Drug Resist; 2021 Mar; 27(3):342-349. PubMed ID: 32762605
[TBL] [Abstract][Full Text] [Related]
47. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
[TBL] [Abstract][Full Text] [Related]
48. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
49. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
50. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by
Daikos GL; da Cunha CA; Rossolini GM; Stone GG; Baillon-Plot N; Tawadrous M; Irani P
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572708
[No Abstract] [Full Text] [Related]
51. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
52. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
[TBL] [Abstract][Full Text] [Related]
53. Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
Gill CM; Nicolau DP;
Antimicrob Resist Infect Control; 2022 Nov; 11(1):146. PubMed ID: 36451179
[TBL] [Abstract][Full Text] [Related]
54. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
55. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
56. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Poirel L; Ortiz De La Rosa JM; Kieffer N; Dubois V; Jayol A; Nordmann P
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323045
[TBL] [Abstract][Full Text] [Related]
57. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
58. Susceptibility profile and β-lactamase content of global
Karlowsky JA; Lob SH; Estabrook MA; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2023 Jun; 5(3):dlad080. PubMed ID: 37388237
[TBL] [Abstract][Full Text] [Related]
59. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of
Alfouzan W; Dhar R; Mohsin J; Khamis F; Mokaddas E; Abdullah A; Mustafa AS; Otero A; Wanis P; Matar SH; Khalil S; Alekseeva I; Young K
JAC Antimicrob Resist; 2022 Apr; 4(2):dlac035. PubMed ID: 35465239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
